PMID- 35463310
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - LncRNA HCG11 Facilitates Nasopharyngeal Carcinoma Progression Through Regulating 
      miRNA-490-3p/MAP3K9 Axis.
PG  - 872033
LID - 10.3389/fonc.2022.872033 [doi]
LID - 872033
AB  - PURPOSE: Long noncoding RNAs (LncRNAs) play complex but important roles in the 
      progression of various tumors. This study aimed to elucidate the functional 
      mechanisms of the HLA complex group 11 (HCG11) in nasopharyngeal carcinoma (NPC). 
      PATIENTS AND METHODS: HCG11 levels in NPC specimens were determined by 
      fluorescence in situ hybridization (FISH) and qPCR. Proliferation, apoptosis, and 
      metastasis of NPC cells were determined using CCK8, colony formation, annexin 
      V-PI, and transwell assays. A murine tumor xenograft model was used to 
      investigate the regulatory function of HCG11 in NPC in vivo, and 
      immunohistochemical staining was used to determine the Ki-67 level in tumors. The 
      target relationships between HCG11, microRNA miR-490-3p, and MAPK kinase kinase 9 
      (MAP3K9) were detected using bioinformatics, qPCR, western blotting, and 
      luciferase reporter assays. RESULTS: HCG11 was highly expressed in NPC tissues 
      and was positively associated with tumor stage, lymphatic metastasis, and poor 
      prognosis. Functionally, HCG11 knockdown inhibited proliferation and migration 
      and induced apoptosis of NPC cells. Mechanistically, miR-490-3p is a direct 
      target of HCG11, oncogenic functions of HCG11 in NPC cell proliferation and 
      migration can be partially reversed by the miR-490-3p inhibitor. HCG11 
      significantly increased mitogen-activated protein kinase MAPK kinase 9 (MAP3K9) 
      levels by inhibiting miR-490-3p. CONCLUSION: HCG11 facilitates NPC progression 
      via MAP3K9 signaling by sponging miRNA-490-3p, which may contribute to new 
      prognostic markers and promising therapeutic targets.
CI  - Copyright (c) 2022 Zheng, Zhao, Ren, Wang, Meng, Zhang, Zhang, Ming and Lu.
FAU - Zheng, Jian
AU  - Zheng J
AD  - Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, China.
FAU - Zhao, Zhuochen
AU  - Zhao Z
AD  - Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, China.
AD  - Key Clinical Laboratory of Henan Province, Zhengzhou, China.
FAU - Ren, Huijun
AU  - Ren H
AD  - Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, China.
AD  - Key Clinical Laboratory of Henan Province, Zhengzhou, China.
FAU - Wang, Yongfeng
AU  - Wang Y
AD  - Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, China.
AD  - Key Clinical Laboratory of Henan Province, Zhengzhou, China.
FAU - Meng, Xianchun
AU  - Meng X
AD  - Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, China.
AD  - Key Clinical Laboratory of Henan Province, Zhengzhou, China.
FAU - Zhang, Wenjing
AU  - Zhang W
AD  - Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, China.
FAU - Zhang, Cai
AU  - Zhang C
AD  - Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, China.
AD  - Key Clinical Laboratory of Henan Province, Zhengzhou, China.
FAU - Ming, Liang
AU  - Ming L
AD  - Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, China.
AD  - Key Clinical Laboratory of Henan Province, Zhengzhou, China.
FAU - Lu, Xiubo
AU  - Lu X
AD  - Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20220407
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9021694
OTO - NOTNLM
OT  - HCG11
OT  - MAP3K9
OT  - miR-490-3p
OT  - nasopharyngeal carcinoma
OT  - nasopharyngeal carcinoma progression
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/04/26 06:00
MHDA- 2022/04/26 06:01
PMCR- 2022/01/01
CRDT- 2022/04/25 05:19
PHST- 2022/02/09 00:00 [received]
PHST- 2022/03/04 00:00 [accepted]
PHST- 2022/04/25 05:19 [entrez]
PHST- 2022/04/26 06:00 [pubmed]
PHST- 2022/04/26 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.872033 [doi]
PST - epublish
SO  - Front Oncol. 2022 Apr 7;12:872033. doi: 10.3389/fonc.2022.872033. eCollection 
      2022.